R2-MANT

Phase 3Small molecule

FFondazione Italiana Linfomi - ETS

R2-MANT is one of 8 small molecule programs targeting Lymphoma, Follicular. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, FollicularActive, not recruiting

Lymphoma, FollicularPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Lymphoma, Follicular

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

1 2

Adriamycin

Pfizer

Phase 2

1 3

Oncovin

Eli Lilly

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 5

Rayos

RRoxane Laboratories

Phase 2

1 6

Treanda

AAzurity Pharmaceuticals

Phase 2

1 7

Golcadomide

Bristol-Myers Squibb

Phase 2

1 8

R2-MANT

FFondazione Italiana Linfomi - ETS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Lymphoma, Follicular

NCT02390869

Clinical

Trials by Indication[1]

Lymphoma, Follicular1 trial

A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).

Active, not recruiting·FFondazione Italiana Linfomi - ETS·Phase 3·NCT02390869·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R2-MANT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R2-MANT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R2-MANT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione Italiana Linfomi - ETS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFondazione Italiana Linfomi - ETS

R2-MANT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Lymphoma, Follicular1 trial

References

Drug Info

Quick Facts

Related News